Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 36-Week Extension to Protocol ISA04-03 to Evaluate the Safety and Efficacy of ISA247 in Patients With Plaque Psoriasis

NCT00258713 is registered in ClinicalTrials.gov with Aurinia Pharmaceuticals Inc. as lead sponsor.

NCT NCT00258713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00258713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 36-Week Extension to Protocol ISA04-03 to Evaluate the Safety and Efficacy of ISA247 in Patients With Plaque Psoriasis
Lead sponsor
Aurinia Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2005
Completion date
July 31, 2006
Enrollment
309 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis